Clinical trials: TACE
Cancer, Metastatic Cancer
Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases
Trans arterial chemoembolization (TACE) has emerged as a treatment option for chemotherapy-refractory diseases in Liver metastases.
- Conditions
- Cancer, Metastatic Cancer, Liver Metastases
- Trial name
- NCT06311851
- Testing
- Bevacizumab
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Pardis Noor Medical Imaging and Cancer Center
Hepatocellular Carcinoma
Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria
The purpose of this study is to evaluate the efficacy and safety of lenvatinib combined with PD-1 antibody compared with transarterial chemoembolization (TACE) for patients with intermediate-stage hepatocellular carcinoma (HCC)…
- Trial name
- NCT03791918
- Testing
- Lenvatinib, PD-1 antibody, TACE
- Where
- 3 sites in China
- Sponsor
- Sun Yat-sen University
Advanced Hepatocellular Carcinoma, Anti-PD1/PDL1 Antibody
Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma
Atezolizumab + Bevacizumab was superior to sorafenib in overall survival in advanced hepatocellular carcinoma. The programmed cell death protein-1 (PD1) and PDL1 inhibitor, was effective and tolerable in patients with advanced…
- Conditions
- Advanced Hepatocellular Carcinoma, Anti-PD1/PDL1 Antibody, Bevacizumab
- Trial name
- NCT06323382
- Testing
- Locoregional therapy, Bevacizumab, Atezolizumab
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma, Cholangiocarcinoma
Liver Embolization Approaches for Tumor Management
The goal of this evaluate short, medium and long term outcome of the different embolization techniques in patients with primary and secondary hepatic tumors.
- Conditions
- Hepatocellular Carcinoma, Cholangiocarcinoma, Metastatic Colon Cancer, Metastatic Cancer
- Trial name
- LEATUM (NCT05714124)
- Testing
- Embolization
- Where
- Italy
- Volunteers
- 580 people
- Sponsor
- IRCCS San Raffaele
HCC
A Multicenter, Prospective Study of Perioperative Finotonlimab Combined With Bevacizumab in Resectable Hepatocellular Carcinoma Patients With High-Risk Factors for Recurrence
For patients with early- to mid-stage hepatocellular carcinoma (HCC), the five-year postoperative recurrence and metastasis rate remains as high as 70%, significantly impacting patient prognosis.Therefore, perioperative therapy…
- Trial name
- NCT07009470
- Testing
- Finotonlimab (an anti-PD-1 monoclonal antibody) and Anbeizhu (a bevacizumab biosimilar), TACE
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma
Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE)
This is a phase IB study design planned to identify the MTD (Maximum Tolerated Dose) of Tocilizumab in HCC (Hepatocellular Carcinoma) patients followed by a phase II design whereupon the primary objective will be median…
- Trial name
- NCT02997956
- Testing
- Tocilizumab, Transcatheter Arterial Chemoembolization
- Where
- United States
- Sponsor
- University of Michigan Rogel Cancer Center
Cadonilimab and Lenvatinib
Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular Carcinoma
This study is a single-arm, open-label, exploratory clinical trial designed to assess the effectiveness and safety of the combination therapy of Cadonilimab and Lenvatinib for conversion treatment in unresectable hepatocellular…
- Trial name
- NCT06215651
- Testing
- Cadonilimab lenvatinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
Resectable Hepatocellular Carcinoma With High Risk of Recurrence
Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo
This is an open-label, single-arm, multicenter, prospective, phase II clinical study to evaluate the efficacy and safety of TACE combined with Atezolizumab and Bevacizumab as neoadjuvant treatment in Hepatocellular Carcinoma.
- Trial name
- ATTACH (NCT07239245)
- Testing
- Atezolizumab, Bevacizumab, Transarterial chemoembolization (TACE)
- Where
- 4 sites in China
- Volunteers
- 30 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Hepatocellular Carcinoma
Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC
This study evaluates the addition of nivolumab to TACE/TAE in the treatment of patients with intermediate stage hepatocellular carcinoma. All patients will receive TACE/TAE and half will receive nivolumab.
- Trial name
- TACE-3 (NCT04268888)
- Testing
- Nivolumab and TACE/TAE, TACE/TAE
- Where
- 2 sites in France, United Kingdom
- Volunteers
- 522 people
- Sponsor
- The Clatterbridge Cancer Centre NHS Foundation Trust
Colorectal Cancer
Irinotecan -Eluting LC Bead-M1 (DEBIRI-M1) for Patients With Liver Metastases From Colorectal Cancer
Purpose: The purpose of this study is to determine the feasibility and safety of using small beads (70-150 micron in place of 100-300 micron) to deliver chemotherapy into the liver to treat patients with liver lesions from…
- Trial name
- NCT02015754
- Testing
- DEBIRI, LC Bead M1, TACE
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Yale University
Transarterial Chemoembolization, Systemic Therapy
Prospective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular Carcinoma
The malignant degree of middle and advanced liver cancer is very high, and the survival prognosis of patients is very poor. TACE is currently the standard treatment for unresectable liver cancer recommended by several…
- Conditions
- Transarterial Chemoembolization, Systemic Therapy, Unresectable Hepatocellular Carcinoma
- Trial name
- NCT06788353
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma, Programmed Cell Death 1
Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC
China is a high-risk area of Hepatocellular Carcinoma (HCC). Although Chinese population accounts for 18.4% of the global population, the number of new HCC patients accounting for about half of the global, which seriously…
- Conditions
- Hepatocellular Carcinoma, Programmed Cell Death 1, Effects of Immunotherapy
- Trial name
- NCT05420922
- Testing
- Lenvatinib Oral Product, PD-1 inhibitor, Local treatment
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma (HCC)
Outcome of Transarterial Chemo-embolization (TACE) in Hepatocellular Carcinoma Patients With Partial Portal Vein Thrombosis
Portal vein tumor invasion (PVT) is a common complication in HCC. the studyb Aimed to assess the outcomes after TACE in patients with branch PVT regarding Child classification, radiological response and 1 year survival.
- Trial name
- NCT03007212
- Testing
- transarterial chemoembolization versus the standard treatment with sorafinib
- Volunteers
- 30 people
- Sponsor
- Ain Shams University
Hepatocellular Carcinoma
Sorafenib and Transarterial Chemoembolization for Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) as the third most common cause of cancer-related death has a very poor prognosis. Aim of this open label single arm non randomized pilot trial is the evaluation of the efficacy and safety of…
- Trial name
- NCT00768937
- Testing
- Sorafenib, Transarterial chemoembolisation (TACE)
- Where
- Austria
- Volunteers
- 22 people
- Sponsor
- Medical University of Vienna
Hepatocellular Carcinoma
Multi-Detector CT Angiography With 3D Reconstruction Versus Digital Subtraction Angiography
This study aims to investigate the feasibility and accuracy of Multi-Detector CT angiography acquired before Trans-arterial Chemo-embolization (TACE) in detecting Hepato-cellular carcinoma feeding vessels compared to DSA…
- Trial name
- NCT05304572
- Testing
- Multi-Detector CT angiography, Trans-arterial chemoembolization and DSA
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Assiut University
Hepatocellular Carcinoma, Bilirubinemia
Safety of Transarterial Chemoembolization (TACE) in the Setting of an Elevated Bilirubin
The aim of this study is to evaluate the safety of selective transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) in the setting of an elevated total bilirubin, but relatively normal direct bilirubin.
- Trial name
- NCT03259581
- Testing
- Transarterial chemoembolization
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Minnesota
Transarterial Chemoembolization, TACE(Transcatheter Arterial Chemoembolization)
Effectiveness of Enhanced Web-Based Health Education on Self-Care Practices and Quality of Life Among Patients With Hepatocellular Carcinoma Undergoing TACE
This randomized controlled trial aims to evaluate the effectiveness of enhanced web-based health education on self-care practices and quality of life among patients with hepatocellular carcinoma.
- Conditions
- Transarterial Chemoembolization, TACE(Transcatheter Arterial Chemoembolization), Web-based Intervention, Quality of Life
- Trial name
- NCT07825519
- Testing
- Enhanced Web-Based Health Education, Routine Health Education
- Where
- Vietnam
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- University Medical Center Ho Chi Minh City (UMC)
Hepatocellular Carcinoma
Randomized Phase II Trial of Chemoembolization and Sorafenib
The study will be a single-center, randomized Phase II study of conventional TACE in combination with sorafenib, given either continuously or sequentially, in patients with unresectable HCC.
- Trial name
- NCT02908165
- Testing
- conventional TACE in combination with sorafenib, administered on a continuous schedule, conventional TACE in combination with sorafenib, administered on a sequential schedule
- Where
- United States
- Sponsor
- Yale University
Hepatocellular Carcinoma
The AI Prognostic Assessment and Pathological Basis Research of Early HCC After Minimally Invasive Treatment
The study evaluates artificial intelligence method based on multimodal magnetic resonance imaging (MRI) images and clinical data in preoperative prediction of prognosis in early hepatocellular carcinoma (HCC) patients treated…
- Trial name
- NCT04299919
- Testing
- Minimally invasive treatment, Hepatectomy
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
Hepatocellular Carcinoma, Adjuvant Therapy
A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection
This is an open label, multi-center, phaseⅡstudy to evaluate the efficacy and safety of TACE sequential tislelizumab as adjuvant therapy in hepatocellular carcinoma (HCC) patients who are at high risk of recurrence after curative…
- Trial name
- NCT04981665
- Testing
- Tislelizumab, TACE
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhejiang University